NCT06375499View on ClinicalTrials.gov

Comparison of the Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.

NACompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

September 17, 2024

Primary Completion Date

January 6, 2025

Study Completion Date

January 6, 2025

Conditions
Dry Eye Syndrome
Interventions
DEVICE

T2769

Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.

DEVICE

Hylo-Forte®

Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.

Trial Locations (4)

4281

Ermellek Egeszsegcentrum, Létavértes

7621

Ganglion Medical Center, Pécs

11800

OFTEX, s.r.o., Prague

15000

Axon Clinical, s.r.o., Prague

Sponsors

Lead Sponsor

Laboratoires Thea
All Listed Sponsors
lead

Laboratoires Thea

INDUSTRY

NCT06375499 - Comparison of the Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome. | Biotech Hunter | Biotech Hunter